Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Pennock S, Rheaume MA, Mukai S, Kazlauskas A.

Am J Pathol. 2011 Dec;179(6):2931-40. doi: 10.1016/j.ajpath.2011.08.043. Epub 2011 Oct 28.

2.

Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11.

Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, Itoh B, Wang J, Komatsu Y, Yang YR, Hikasa H, Horie Y, Yamashita T, Kamijo T, Zhang Y, Zhu Y, Prives C, Nakano T, Mak TW, Sasaki T, Maehama T, Mori M, Suzuki A.

Nat Med. 2011 Jul 31;17(8):944-51. doi: 10.1038/nm.2392.

3.

Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin.

Qiu J, Wang G, Hu J, Peng Q, Zheng Y.

Mol Cell Biochem. 2011 Nov;357(1-2):125-33. doi: 10.1007/s11010-011-0882-6. Epub 2011 Jun 1.

PMID:
21630092
4.

Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR).

Telander DG, Morales SA, Mareninov S, Forward K, Gordon LK.

Curr Eye Res. 2011 Jun;36(6):546-52. doi: 10.3109/02713683.2011.561468.

5.

Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, Wilson M, Stewart C, Zhu F, Guy K, Dyer MA.

Cancer Res. 2011 Jun 15;71(12):4205-13. doi: 10.1158/0008-5472.CAN-11-0058. Epub 2011 Apr 22.

6.

Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 and epithelial membrane protein 2 components of the tetraspan web.

Morales SA, Telander D, Notterpek L, Wadehra M, Braun J, Gordon LK.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5465-72. doi: 10.1167/iovs.10-6139.

7.

Recent advances in the therapeutic perspectives of Nutlin-3.

Secchiero P, Bosco R, Celeghini C, Zauli G.

Curr Pharm Des. 2011;17(6):569-77. Review.

PMID:
21391907
8.

Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Lei H, Velez G, Kazlauskas A.

Mol Cell Biol. 2011 May;31(9):1788-99. doi: 10.1128/MCB.01321-10. Epub 2011 Feb 28.

9.

Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells.

Loewer A, Batchelor E, Gaglia G, Lahav G.

Cell. 2010 Jul 9;142(1):89-100. doi: 10.1016/j.cell.2010.05.031.

10.

N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A.

Am J Pathol. 2010 Jul;177(1):132-40. doi: 10.2353/ajpath.2010.090604. Epub 2010 May 20.

11.

Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Lei H, Rheaume MA, Kazlauskas A.

Exp Eye Res. 2010 Mar;90(3):376-81. doi: 10.1016/j.exer.2009.11.003. Epub 2009 Nov 25. Review.

12.

The first 30 years of p53: growing ever more complex.

Levine AJ, Oren M.

Nat Rev Cancer. 2009 Oct;9(10):749-58. doi: 10.1038/nrc2723. Review.

13.

Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Morales SA, Mareninov S, Coulam P, Wadehra M, Goodglick L, Braun J, Gordon LK.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4949-56. doi: 10.1167/iovs.08-3315. Epub 2009 Jun 3.

14.

Growth factors outside the PDGF family drive experimental PVR.

Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3394-403. doi: 10.1167/iovs.08-3042. Epub 2009 Mar 25.

16.

PDGF receptors are activated in human epiretinal membranes.

Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, Kazlauskas A.

Exp Eye Res. 2009 Mar;88(3):438-44. doi: 10.1016/j.exer.2008.10.020. Epub 2008 Nov 8.

17.

Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.

Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M.

Mol Cell. 2008 Oct 24;32(2):180-9. doi: 10.1016/j.molcel.2008.08.031.

18.

FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction.

Morales SA, Mareninov S, Wadehra M, Zhang L, Goodglick L, Braun J, Gordon LK.

Invest Ophthalmol Vis Sci. 2009 Jan;50(1):462-9. doi: 10.1167/iovs.07-1598. Epub 2008 May 9.

19.

Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway.

Morales SA, Mareninov S, Prasad P, Wadehra M, Braun J, Gordon LK.

Exp Eye Res. 2007 Dec;85(6):790-8. Epub 2007 Aug 29.

PMID:
17915217
20.

Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.

Schiff WM, Hwang JC, Ober MD, Olson JL, Dhrami-Gavazi E, Barile GR, Chang S, Mandava N.

Arch Ophthalmol. 2007 Sep;125(9):1161-7.

PMID:
17846353

Supplemental Content

Support Center